#Novartis' oral #BTKinhibitor #Rhapsido has had its label expanded in the #US to include a second indication, #symptomaticdermographism (SD), which causes #chronichives.
@pharmaphorum.bsky.social@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#Novartis' oral #BTKinhibitor #Rhapsido has had its label expanded in the #US to include a second indication, #symptomaticdermographism (SD), which causes #chronichives.